Oaktree Acquisition Corp. III Life Sciences (OACC) Liabilities and Shareholders Equity (2024 - 2026)
Oaktree Acquisition Corp. III Life Sciences filings provide 3 years of Liabilities and Shareholders Equity readings, the most recent being $204.8 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 3.85% to $204.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $808.4 million through Mar 2026, changed N/A year-over-year, with the annual reading at $203.1 million for FY2025, 4.03% up from the prior year.
- Liabilities and Shareholders Equity hit $204.8 million in Q1 2026 for Oaktree Acquisition Corp. III Life Sciences, up from $203.1 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $204.8 million in Q1 2026 and bottomed at $195.3 million in Q4 2024.
- Average Liabilities and Shareholders Equity over 3 years is $200.1 million, with a median of $200.2 million recorded in 2025.
- The largest annual shift saw Liabilities and Shareholders Equity increased 4.03% in 2025 before it grew 3.85% in 2026.
- Oaktree Acquisition Corp. III Life Sciences' Liabilities and Shareholders Equity stood at $195.3 million in 2024, then grew by 4.03% to $203.1 million in 2025, then rose by 0.85% to $204.8 million in 2026.
- Per Business Quant, the three most recent readings for OACC's Liabilities and Shareholders Equity are $204.8 million (Q1 2026), $203.1 million (Q4 2025), and $201.2 million (Q3 2025).